abrdn Healthcare Investors Q1 2025 Commentary
Source: SeekingAlpha
2025-05-30 09:05:00 ET
Summary
- The equity portion of the Fund fell (gross of fees) and underperformed its benchmark over the quarter.
- During the first quarter of 2025, we made several changes to the portfolio.
- The top three detractors were Sarepta Therapeutics, Regeneron Pharmaceuticals and Vaxcyte.
- With Donald Trump securing his second term, uncertainty around election results has been replaced with policy ambiguity.
Fund performance
The equity portion of the Fund fell (gross of fees) and underperformed its benchmark over the quarter.[1]...
Read the full article on Seeking Alpha
For further details see:
abrdn Healthcare Investors Q1 2025 Commentary
Aberdeen Australia Equity Fund Inc
NASDAQ: IAF
IAF Trading
-0.94% G/L:
$12.6801 Last:
47,636 Volume:
$12.71 Open:
IAF Latest News
February 10, 2026 04:17:00 pm
Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
October 08, 2025 04:17:00 pm
ABRDN AUSTRALIA EQUITY FUND, INC. ANNOUNCES DETAILS OF UPCOMING 1-FOR-3 REVERSE STOCK SPLIT
